FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Soni Manmeet Singh 		2. Issuer Name and Ticker or Trading Symbol

PHARMACYCLICS INC [ PCYC ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/26/2015
(Street)

SUNNYVALE, CA 94085
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/26/2015     D    54000   (1) D $261.25   873   (2) D    
Common Stock   5/26/2015     U    873   D $261.25   (3) 0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock (Right to Buy)   $61.60   5/26/2015     D         11152      (4) 10/26/2022   Common Stock   11152     (4) 0   D    
Common Stock (Right to Buy)   $70.37   5/26/2015     D         18750      (4) 2/12/2023   Common Stock   18750     (4) 0   D    
Common Stock (Right to Buy)   $106.75   5/26/2015     D         15000      (4) 8/16/2023   Common Stock   15000     (4) 0   D    
Common Stock (Right to Buy)   $138.66   5/26/2015     D         8000      (4) 2/28/2024   Common Stock   8000     (4) 0   D    
Common Stock (Right to Buy)   $102.22   5/26/2015     D         40000      (4) 4/2/2024   Common Stock   4000     (4) 0   D    

Explanation of Responses:
( 1)  Represents shares issuable pursuant to a Restricted Stock Unit Award that was cancelled in exchange for a cash payment, subject to applicable withholding taxes and pursuant to the procedures terms set forth in the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie.
( 2)  Includes 262 shares acquired under the Pharmacyclics, Inc. Employee Stock Purchase Plan on April 30, 2015.
( 3)  Price reflects aggregate per share consideration paid pursuant to the Tender Offer.
( 4)  This option was cancelled pursuant to the terms of the Merger Agreement in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Soni Manmeet Singh
C/O PHARMACYCLICS, INC.
995 EAST ARQUES AVE
SUNNYVALE, CA 94085

Chief Financial Officer

Signatures
/s/ Manmeet S. Soni 5/27/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
(MM) (NASDAQ:PCYC)
過去 株価チャート
から 11 2024 まで 12 2024 (MM)のチャートをもっと見るにはこちらをクリック
(MM) (NASDAQ:PCYC)
過去 株価チャート
から 12 2023 まで 12 2024 (MM)のチャートをもっと見るにはこちらをクリック